Alzheimer's Drug Discovery Foundation

The Alzheimer's Drug Discovery Foundation
FounderLeonard A. Lauder, Ronald S. Lauder
FocusAlzheimer's Disease Preclinical Drug Research, Program to Accelerate Clinical Trials, Cognitive Vitality and Prevention, ADDF Access
Location
  • New York, NY
Key people
Dr. Howard Fillit, Executive Director and Chief Science Officer
WebsiteOfficial website

The Alzheimer's Drug Discovery Foundation (ADDF) is a nonprofit organization founded in 1998 by co-chairmen Leonard A. Lauder and Ronald S. Lauder of the Estée Lauder Companies cosmetics family [1] and led by Howard Fillit,[2] a geriatrician and neuroscientist. The ADDF provides funding to scientists who are conducting promising, innovative Alzheimer's disease drug research worldwide.[3][4][5] The ADDF funds early-stage research and early-phase clinical trials that might otherwise go unfunded.[6] By supporting research projects around the world, it seeks to increase the chances of finding treatments for Alzheimer's disease, related dementias and cognitive aging.[7][8][9] The ADDF has invested nearly $65 million to fund some 450 Alzheimer's drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries.[3]

The ADDF also publishes peer-reviewed scientific articles with the goal of accelerating and improving Alzheimer's disease drug discovery research.[10][11][12]

  1. ^ "Topics: Leonard Lauder". Wall Street Journal. Retrieved April 2, 2014.
  2. ^ "Staff - Alzheimer's Drug Discovery Foundation - Alzheimer's Drug Discovery Foundation". www.alzdiscovery.org.
  3. ^ a b "About ADDF". Alzheimer's Drug Discovery Foundation. Retrieved April 2, 2014.
  4. ^ Donnelly, Shannon (May 22, 2013). "Alzheimer's Drug Discovery Foundation features Paula Zahn, raises more than $2 million". Palm Beach Daily News. Palm Beach, FL: Cox Media Group. Retrieved April 2, 2014.
  5. ^ Bertagnoli, Lisa (November 5, 2012). "Lauder, Crowns bring Alzheimer's fight to Chicago". Chicago Business. Crain Communications, Inc. Retrieved April 2, 2014.
  6. ^ "ADDF Research Portfolio". Alzheimer's Drug Discovery Foundation. Retrieved April 2, 2014.
  7. ^ "Patient Organizations - National Institute of Neurological Disorders and Stroke". www.ninds.nih.gov.
  8. ^ Sullivan, Paul (December 24, 2012). "Making an Argument for a Narrower Focus in Charitable Donations". New York Times. Retrieved April 2, 2014.
  9. ^ Shriver, Maria (September 2, 2013). "Why isn't more being done for Alzheimer's research?". MSNBC. Retrieved April 2, 2014.
  10. ^ Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjänheikki J, Fillit HM (2011). "Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies". Alzheimers Res Ther. 3 (5): 28. doi:10.1186/alzrt90. PMC 3218805. PMID 21943025.
  11. ^ Dacks, P.A.; Shineman, D.W.; Fillit, H.M. (March 17, 2013). "Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease". The Journal of Nutrition, Health and Aging. 17 (3): 240–51. doi:10.1007/s12603-012-0431-3. PMID 23459977. S2CID 23548988.
  12. ^ Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, Mielke MM, O'Bryant S, Sarasa M, Sjøgren M, Soares H, Teeling J, Trushina E, Ward M, West T, Bain LJ, Shineman DW, Weiner M, Fillit HM (2014). "Developing novel blood-based biomarkers for Alzheimer's disease". Alzheimer's & Dementia. 10 (1): 109–14. doi:10.1016/j.jalz.2013.10.007. PMC 4769619. PMID 24365657.